How this U.S.-made, $176,000 anti-tank weapon could change the war in Ukraine

How this U.S.-made, 6,000 anti-tank weapon could change the war in Ukraine


Ukraine’s defense against Russia is being supported by billions of dollars in military aid from NATO countries. One of the most capable and expensive weapon systems supplied is the FGM-148 Javelin, a U.S.-made anti-armor weapon that costs about $176,000 each.

“We don’t know where and when the next kinetic war will be, and producing new weapons, surging production lines takes time,” said Cynthia Cook, a senior fellow at the Center for Strategic and International Studies. “This may be a time where we might want to think about how we invest in increasing the inventory of precision-guided weapons and other weapons and missiles.”

Although the Javelin has been lauded by the Ukrainian government, the actual effectiveness of the weapon system remains hard to independently verify outside of anecdotal accounts from the battlefield.

“We don’t have folks on the ground, and I think that is a policy decision that we should reconsider,” said U.S. Rep. Mark Waltz, R-Fla., a former U.S. Army Green Beret. “We could help them be actually more effective if we had advisors alongside, but we’d have to do that in very small numbers very selectively, and very quietly.”

Watch the video above to find out what the Javelin is, how it it used and what it will take for the U.S. to produce more of them.



Source

AI will supercharge sports team valuations, says Arctos Partners’ Charles
Business

AI will supercharge sports team valuations, says Arctos Partners’ Charles

A version of this article appeared in CNBC’s Inside Alts newsletter, a guide to the fast-growing world of alternative investments, from private equity and private credit to hedge funds and venture capital. Sign up to receive future editions, straight to your inbox. The rise of artificial intelligence is likely to boost the valuations of sports teams and […]

Read More
Disney names parks boss Josh D’Amaro as its next CEO to succeed Bob Iger, effective March 18
Business

Disney names parks boss Josh D’Amaro as its next CEO to succeed Bob Iger, effective March 18

Disney has named Josh D’Amaro, chairman of Disney Experiences, as its next CEO, succeeding Bob Iger and clinching a closely watched succession race at the Mouse House. Investors, industry insiders and onlookers have long awaited the announcement of who will take over as the next leader of one of the most storied U.S. companies. The […]

Read More
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
Business

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Smith Collection | Archive Photos | Getty Images Pfizer on Thursday said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. Patients with obesity or who are overweight lost up to 12.3% of their weight compared with placebo at week 28 in […]

Read More